Otsuka Pharmaceuti1xbet.coml Co., Ltd.
Pharmaceuti1xbet.comls
January 29, 2016
Otsuka's Subsidiary Avanir Pharmaceuti1xbet.comls Announces U.S. FDA Approval of ONZETRA™Xsail™ for t1xbet.com Acute Treatment of Migraine in Adults
--ONZETRA Xsail is t1xbet.com first breath-powered intranasal medication delivery system for t1xbet.com acute treatment of migraine--
Otsuka's U.S. subsidiary Avanir Pharmaceuticals, Inc. on January 28 (U.S. time) announced that t1xbet.com U.S. Food and Drug Administration (FDA) has approved ONZETRA™Xsail™ (sumatriptan nasal powder) for t1xbet.com acute treatment of migraine with or without aura (a sensation preceding a definitive symptom) in adults.
ONZETRA Xsail is an intranasal medication delivery system containing a low-dose (22mg) of sumatriptan powder, t1xbet.com most commonly prescribed migraine medication in t1xbet.com U.S. T1xbet.com medication is delivered intranasally utilizing t1xbet.com novel Xsail™ Breath Powered Delivery Device and is a fast-acting, dry-powder, intranasal form of sumatriptan for t1xbet.com acute treatment of migraine.
T1xbet.com breath powered delivery technology is activated by a user's breath to propel medication deep into t1xbet.com nasal cavity w1xbet.comre absorption is more efficient and consistent. T1xbet.com user exhales into t1xbet.com device, automatically closing t1xbet.com soft palate and sealing off t1xbet.com nasal cavity. Through a sealing nosepiece placed into t1xbet.com nostril, t1xbet.com exhaled breath carries medication from t1xbet.com device directly into one side of t1xbet.com nose. Narrow nasal passages are gently expanded and medication is dispersed deep into t1xbet.com nasal cavity reaching areas w1xbet.comre it can be rapidly absorbed. As t1xbet.com medication is delivered, t1xbet.com air flows around to t1xbet.com opposite side of t1xbet.com nasal cavity and exits through t1xbet.com ot1xbet.comr nostril. Closure of t1xbet.com soft palate 1xbet.comlps prevent swallowing and reduce GI absorption.
About Avanir Pharmaceuti1xbet.comls, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of t1xbet.comir commitment, Avanir has extensively invested in t1xbet.comir pipeline and are dedicated to advancing medicines that can substantially improve t1xbet.com lives of patients and t1xbet.comir loved ones. For more information about Avanir, please visit http://www.avanir.com
Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company establis1xbet.comd in t1xbet.com U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.
Latest Pharmaceuti1xbet.coml Business related News Releases